Regulation of GH-Releasing Hormone Receptors

MAKOTO SATO, TOMOYO OHYAMA, AND JIRO TAKAHARA

First Department of Internal Medicine, Kagawa Medical University, Kagawa 761–07, Japan

SECRETION and gene expression of GH are controlled by hypothalamic GH-releasing hormone (GRH) which acts through a G protein-coupled receptor, GRH receptor, resulting in activation of cyclic AMP and A-kinase systems in the somatotropes [1]. Many humoral factors affect GH responses to GRH [1] and some of their effects may be caused by qualitative and quantitative changes in GRH receptors. Glucocorticoids are one of the most important factors modifying GH secretion and gene expression. Many lines of evidence indicated that glucocorticoids stimulate GH secretion and gene expression at least by their acute effects [2–5]. It has also been reported that dexamethasone (Dex) increases GRH binding sites in the rat pituitary membrane [6]. We therefore questioned whether Dex regulates GRH receptor gene expression, since most of the biological effects of glucocorticoids are attributed to their genomic actions on target genes in many types of cells [7].

To investigate GRH receptor gene expression at mRNA levels, a highly-sensitive method is required, because GRH receptor mRNA content is very low even in the anterior pituitary [8]. Conventional Northern blot analysis of total RNA in the pituitary tissue of a single rat fails to detect this low-abundant mRNA. Polymerase chain reaction (PCR) is extremely sensitive and quantitative PCR is useful for examining the regulation of GRH receptor mRNA levels. We previously established a competitive reverse transcription (RT)-PCR method [9, 10]. In the present study, we examined the effects of Dex on GRH receptor mRNA levels by using the competitive RT-PCR method. In vitro, the effects of Dex on GRH receptor mRNA levels were examined with the primary culture system of rat anterior pituitary cells. In vivo, rats were exposed to Dex or glucocorticoid deficiency due to adrenalectomy, and GRH receptor mRNA levels were examined in the anterior pituitary tissue.

Materials and Methods

Competitive RT-PCR method was used to quantify GRH receptor mRNA levels as previously described [10]. Briefly, total RNA was extracted from rat anterior pituitary tissues or cultured rat anterior pituitary cells. The stock competitor (recombinant RNA) was diluted from 10 pg to 10 fg by 10-fold serial dilutions. Five hundred nanograms of each total RNA and diluted competitor were added to the same microtube and reverse transcribed into cDNA with random primers. Thirty cycles of PCR were carried out in a thermal cycler based on a step program of 94 °C for 80 sec, 49 °C for 80 sec, 72 °C for 80 sec, followed by a 15-min extension at 72 °C. PCR products were electrophoresed on an 1.5% agarose gel containing ethidium bromide and photographed. Signal intensities of each product were quantified with an image analyzer. The concentration of GRH receptor mRNA was calculated by regression analyses of samples and competitors.

The primary culture system of rat anterior pituitary cells was prepared as previously described [11]. The cells were treated with Dex 4 days after preparation and the dose- and time-dependent effects of Dex on GRH receptor mRNA levels were examined with total RNA extracted from the treated
cells. In a separate series of experiments, a glucocorticoid receptor-specific antagonist, RU38486 (Roussel UCLAF, Paris, France), was added to the cells in the presence of Dex. For in vivo studies, male adult Wistar rats were used. Dex was administered to the rats by ip injection and they were killed by decapitation 24 h after the single injection. Total RNA was extracted from rat anterior pituitary tissues to examine GRH receptor mRNA levels. In the next series of experiments, rats underwent adrenalectomy to remove endogenous glucocorticoids. Vehicle and Dex were administered to the glucocorticoid-deficient animals. Anterior pituitary tissues were obtained 3 days after surgery to examine GRH receptor mRNA levels. Statistical comparisons were made by one-way analysis of variance and Student’s t-test, with P<0.05 being considered significant.

**Results**

Cultured rat anterior pituitary cells were treated with Dex at several concentrations for 24 h. GRH receptor mRNA levels were significantly increased by Dex at a concentration of 5 nM and the maximal effect was noted at 25 nM (Fig. 1). Time-course effects of Dex were examined in the next series of experiments. The concentration of Dex was adjusted to 5 nM in these experiments. GRH receptor mRNA levels were not altered by 2-h incubation with Dex, but the 6-h incubation significantly increased GRH receptor mRNA levels in the cultured rat anterior pituitary cells (Fig. 2). This stimulatory effect of Dex persisted until at least 24 h after treatment. A glucocorticoid receptor specific antagonist, RU 38468, significantly inhibited Dex-induced increase in GRH receptor mRNA levels (Fig. 3).

In the first series of in vivo studies, a single ip injection of Dex had not significantly altered pituitary GRH receptor mRNA levels 24 h after the injection (Fig. 4). Changes in GRH receptor mRNA levels were similar when much lower doses of Dex were used in the same protocol. Even longer exposure to a high dose (200 µg/rat) of Dex for up to 3 weeks did not significantly alter pituitary GRH receptor mRNA levels. Figure 5 shows the effects of adrenalectomy on pituitary GRH receptor mRNA levels in rats. GRH receptor mRNA levels were significantly decreased 3 days after adrenalectomy,
but when the glucocorticoid-deficient rats received a daily administration of 50 μg of Dex for 3 days, pituitary GRH receptor mRNA levels returned to normal (Fig. 5).

Discussion

Our in vitro studies indicated that Dex stimulates GRH receptor mRNA expression in rat somatotropes. This effect was dose- and time-dependent, and blocked by the glucocorticoid receptor specific antagonist, RU 38486. These findings suggest that Dex stimulates the transcriptional activity of the GRH receptor gene through the glucocorticoid receptors. Glucocorticoids activate many genes at the transcriptional level [7]. Ligand-activated GC receptor homodimers bind to characteristic DNA response elements (glucocorticoids response elements: GREs) [12]. Since there are no GREs in the promoter region of rat GRH receptor gene (personal communication), direct interaction between glucocorticoids and GRH receptor genes seems unlikely in Dex-induced enhancement of GRH receptor mRNA levels. Instead, glucocorticoids may enhance the stability of GRH receptor mRNAs as demonstrated in several other genes [13, 14]. In the present study, stimulatory actions of Dex in GRH receptor mRNA levels were delayed, requiring more than 2 h at least. This also suggests that the Dex-induced increase in GRH receptor mRNA levels might be due to indirect effects on the stability of GRH receptor mRNA.

Administration of Dex to the rats did not cause a significant increase in GRH receptor mRNA levels. Although a high dose of Dex (200 μg/rat) was administered to the rats daily for a prolonged period (up to 3 weeks), pituitary GRH receptor mRNA levels were not significantly increased. These results indicate that pituitary GRH receptor mRNA levels are less affected by glucocorticoid excess in vivo. A considerable number of reports have previously shown that the effects of glucocorticoids on the GH-regulatory system appear to be different, sometimes even opposite, on comparison of in vitro and in vivo results [15]. Hypothalamic modification by GRH and somatostatin, and metabolic influence may modify glucocorticoid actions, and we do not preclude the possibility that the doses and ways of Dex administration might be responsible for the lack of its stimulatory effect on GRH receptor mRNA levels in vivo.

On the other hand, GRH receptor mRNA levels were significantly lowered in glucocorticoid-deficient rats after adrenalectomy. Furthermore, replacement of Dex normalized the pituitary GRH
receptor mRNA levels in these animals. Seifert et al. [6] previously reported that adrenalectomy decreased GRH binding sites in rat anterior pituitary membrane homogenates. Taken together, these findings imply that physiological levels of endogenous glucocorticoids are necessary for normal expression of pituitary GRH receptors at both mRNA and protein levels. This might, at least partly, explain the pathogenesis of GH impairment observed in patients with glucocorticoid deficiency. Giustina et al. [16] have reported that GH responses to insulin-induced hypoglycemia and arginine infusion are suppressed in patients with isolated ACTH deficiency. Since such provocation tests appear to act through the stimulation of hypothalamic GRH secretion [1], GH response to GRH appears impaired in glucocorticoid-deficient patients.

In conclusion, our study indicates that Dex enhances GRH receptor gene expression through the glucocorticoid receptors in rat somatotropes. Endogenous glucocorticoid seems therefore to play an important role in regulating GRH receptor gene expression in the rat pituitary.

References
